MYDA Advisors LLC Sells 70,000 Shares of Agilon Health, Inc. $AGL

MYDA Advisors LLC lessened its position in shares of Agilon Health, Inc. (NYSE:AGL) by 58.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after selling 70,000 shares during the period. MYDA Advisors LLC’s holdings in Agilon Health were worth $34,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. North Peak Capital Management LLC increased its holdings in Agilon Health by 10.8% during the 4th quarter. North Peak Capital Management LLC now owns 38,139,937 shares of the company’s stock worth $26,267,000 after purchasing an additional 3,715,460 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Agilon Health by 196.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 20,055,214 shares of the company’s stock worth $13,812,000 after purchasing an additional 13,283,930 shares in the last quarter. CenterBook Partners LP grew its holdings in shares of Agilon Health by 492.4% in the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after acquiring an additional 9,499,012 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Agilon Health by 30.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 8,019,002 shares of the company’s stock valued at $5,523,000 after acquiring an additional 1,893,434 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Agilon Health by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 7,177,477 shares of the company’s stock valued at $4,944,000 after acquiring an additional 35,054 shares during the last quarter.

Agilon Health Trading Down 1.0%

Agilon Health stock opened at $113.19 on Wednesday. Agilon Health, Inc. has a 52 week low of $7.48 and a 52 week high of $118.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.04 and a current ratio of 1.04. The stock has a market capitalization of $1.89 billion, a P/E ratio of -5.25 and a beta of 3.02. The stock has a 50-day simple moving average of $61.29 and a 200 day simple moving average of $32.15.

Agilon Health (NYSE:AGL) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.76. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%.The business had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.38 billion. Analysts expect that Agilon Health, Inc. will post -3.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AGL shares. Citigroup reaffirmed a “neutral” rating and issued a $80.00 target price (up from $18.75) on shares of Agilon Health in a research report on Friday, May 15th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $72.00 target price (up from $37.50) on shares of Agilon Health in a research report on Friday, May 8th. Jefferies Financial Group raised Agilon Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $27.50 to $48.00 in a research report on Thursday, May 7th. JPMorgan Chase & Co. downgraded Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 target price on the stock. in a research report on Monday, May 4th. Finally, Deutsche Bank Aktiengesellschaft raised Agilon Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $33.00 to $49.00 in a research report on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $58.73.

Agilon Health Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.